Wellington Management Group LLP filed Amendment No. 8 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 10,951,399 shares of Celldex Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Wellington Management Group LLP reported beneficial ownership of 10,951,399 shares of Celldex Therapeutics common stock.
  • Percent of class: The aggregate position represents 13.9% of the outstanding class, with Item 4 specifying 13.95%.
  • Shared voting power: Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared voting power over 9,848,552 shares, with zero sole voting power.
  • Shared dispositive power: The three parent holding companies each reported shared dispositive power over 10,951,399 shares, with zero sole dispositive power.
  • Notable client: According to the filing, Vanguard Health Care Fund is identified as a client with the right to receive dividends or proceeds from the sale of the securities with respect to more than 5% of the class.
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Filing entities: Four Wellington entities are named as reporting persons: Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP.

Wellington Management Group's Amended Stake in Celldex Therapeutics

According to Amendment No. 8 to its Schedule 13G, Wellington Management Group LLP, organized in Massachusetts, disclosed that it and three affiliated entities collectively hold 10,951,399 shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) common stock, representing 13.9% of the class. The filing covers common stock with CUSIP number 15117B202 and was triggered by an event dated September 30, 2026. Celldex Therapeutics is headquartered at Perryville III Building, 53 Frontage Road, Suite 220, Hampton, NJ 08827, according to the filing.

The filing identifies four reporting persons, all classified as either holding companies (HC) or investment advisers (IA). Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report identical aggregate beneficial ownership of 10,951,399 shares and shared dispositive power over that full amount. Wellington Management Company LLP, classified as an investment adviser, reports shared voting power over 9,826,453 shares and shared dispositive power over 10,526,026 shares, also with an aggregate beneficial ownership figure of 10,951,399 shares and a reported percent of class of 13.4%. In all cases, sole voting and sole dispositive power are each listed as zero.

The filing states that the securities are owned of record by clients of one or more Wellington Investment Advisers, which include entities operating across multiple jurisdictions, among them Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd, Wellington Management Hong Kong Ltd, Wellington Management International Ltd, Wellington Management Japan Pte Ltd, and Wellington Management Australia Pty Ltd. The filing further discloses that Vanguard Health Care Fund is a client known to have the right to receive, or the power to direct the receipt of, dividends or proceeds from the sale of securities amounting to more than 5% of the class. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Wellington Management Group LLP and three affiliated entities filed Amendment No. 8 to Schedule 13G reporting combined beneficial ownership of 10,951,399 Celldex Therapeutics shares, equal to 13.9% of the class, as of September 30, 2026, with Vanguard Health Care Fund named as a significant underlying client.